Eli Lilly and Company $LLY Position Reduced by Castleark Management LLC

Castleark Management LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 42.1% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 46,168 shares of the company’s stock after selling 33,524 shares during the period. Eli Lilly and Company makes up about 1.1% of Castleark Management LLC’s investment portfolio, making the stock its 20th largest position. Castleark Management LLC’s holdings in Eli Lilly and Company were worth $35,989,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in LLY. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the first quarter worth $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in shares of Eli Lilly and Company during the 2nd quarter valued at $27,000. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company in the second quarter valued at about $31,000. Bare Financial Services Inc raised its position in Eli Lilly and Company by 263.6% during the second quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares in the last quarter. Finally, Blume Capital Management Inc. lifted its stake in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after purchasing an additional 14 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on LLY shares. Loop Capital set a $950.00 price target on Eli Lilly and Company in a report on Monday, November 10th. Morgan Stanley lifted their price target on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the stock an “overweight” rating in a research note on Monday, November 24th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a research report on Tuesday. Finally, CICC Research lifted their price target on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $1,121.90.

Eli Lilly and Company Stock Up 1.8%

Shares of NYSE LLY opened at $1,027.68 on Friday. The stock has a market cap of $971.55 billion, a P/E ratio of 50.28, a P/E/G ratio of 1.14 and a beta of 0.37. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The firm has a 50 day moving average price of $939.47 and a 200 day moving average price of $819.64.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the prior year, the company earned $1.18 earnings per share. The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio (DPR) is 29.35%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.